Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. - Wikidata - awgldk - TriplyDB

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

http://www.wikidata.org/entity/Q36088957

about

Sin3b interacts with Myc and decreases Myc levels Hbo1 Links p53-dependent stress signaling to DNA replication licensing.Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy.RTA promoter demethylation and histone acetylation regulation of murine gammaherpesvirus 68 reactivation Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells Seed in soil, with an epigenetic view Chemical and biochemical approaches in the study of histone methylation and demethylation Epigenetic changes induced by curcumin and other natural compounds.Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression ATM mediated phosphorylation of CHD4 contributes to genome maintenance.Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis.SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.Epigenetics provides a new generation of oncogenes and tumour-suppressor genes.Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation.Natural chalcones as dual inhibitors of HDACs and NF-κB.Epigenetic aberrations and cancer.The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.Cancer genetics of epigenetic genes.Histone deacetylase inhibitors and transplantation.p53 chromatin epigenetic domain organization and p53 transcription.The epigenetics of adult (somatic) stem cells.Gene clusters, molecular evolution and disease: a speculation.Epigenetic alterations in human prostate cancers.Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance.Pathogenesis of lung cancer signalling pathways: roadmap for therapies.SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer.Effects of Valproic Acid on Radiation-Induced Chromosomal Aberrations in Human Lymphocytes.Epigenetic regulation of cell life and death decisions and deregulation in cancer.Control of RUNX3 by histone methyltransferases.Feedback networks between microRNAs and epigenetic modifications in urological tumors.Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.EZH2, an epigenetic driver of prostate cancer.DNA methylation pattern as important epigenetic criterion in cancer.Impact of Epigenetic Dietary Components on Cancer through Histone Modifications.Comparative analysis of protein-protein interactions in cancer-associated genes.A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer.Corticotropin releasing factor up-regulates the expression and function of norepinephrine transporter in SK-N-BE (2) M17 cells.The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.

P2860

Q24299671-1F43DF13-63C7-480D-A22E-DC58472DD857 Q30442559-F84C797B-7791-4B0C-8B78-0644744DABE5 Q30911744-A5354333-D034-4CFA-BF07-61F87D0B8C65 Q33411313-17783F5C-B461-4584-B67A-2939912B94D5 Q33652855-F716953D-1F10-437F-A9D8-975A97A3CB18 Q33754753-39FF2D38-9C35-4418-AE8A-38DCE9FF89E1 Q34030702-59C67B8E-A02A-4D43-B1F1-B8E051BBCF88 Q34180255-3FE0B759-4112-40F7-A981-DFB12FE47536 Q34271529-21E7EF7B-D220-4181-AE4D-C26AEFDA7E13 Q34462001-2CDBC661-D8A4-4403-A1AB-F5754F5D0347 Q34557700-7B229A23-8DE3-4A0D-B4F9-B316524CA00A Q34997153-687833A7-0EC2-414B-8E65-4FFF21662355 Q35176138-32780D34-7381-4CB2-BE73-4DD8E16A5FD9 Q36148943-7505E018-8A36-4945-BC44-139D7ABEA3C0 Q36365099-0DA9962D-8F16-4BB0-8070-3497A022EC6A Q36579350-F58BE295-828A-4557-8767-405D5574F35A Q36642705-737D98F8-3A4A-4C57-87D6-03CAAD4E5FE8 Q36648081-FD7FFA19-ACC7-47F0-B3BC-67FFA9A9EAB8 Q36782553-EB75142F-69C8-4EEB-9038-77141F4CD88C Q36871595-33A30325-D6BF-4459-B02E-C1C6D9110D48 Q36919214-003726CB-F212-42C6-B075-FC598F79F2F0 Q37033608-DDC28CAA-C748-45E5-AAF8-756900E9815A Q37186709-225D3ED6-43CC-41CB-8C8C-EAE274B5F5D6 Q37236200-AD7BB90A-E85C-48B2-8CE0-21A7427A0D7D Q37328845-860452D6-93D4-4747-A9A1-9E04263BAECE Q37378417-979176D9-3031-4569-90DA-2603DF84DB12 Q37389526-8D9CE3F9-9F1E-4037-B3EE-ACD5E302DA5A Q37551171-0E688B32-E3D4-4CD9-9926-6F12330A4D81 Q37658507-83B3DFBB-9379-4ADC-9069-89492EB41464 Q37785993-D8EA60C9-082C-44EF-A47E-6D698C278383 Q37832455-B170E7CD-7606-4FCD-89E1-B53532F68403 Q37993339-FB1C7BCF-FE1B-4877-9CB0-76BBE7276402 Q38045433-019675D4-4833-49EE-8591-972130A6A1E0 Q38103472-E0E9471E-9E55-4BE9-AEB8-FA13854B5431 Q38181126-F9A21212-3574-4690-87D2-5070F2F2110D Q38428453-AAC6EAC9-4E1E-4C08-B3E8-9FFE83FC546C Q38509626-531236DE-F76C-40CF-BB84-A2536E6402F3 Q38582323-8251FA1D-A118-4C97-BA2C-F271B6195EFE Q38849050-3A43C2BF-E1BB-46AD-992E-2D43D9920747 Q40038178-5227FEA2-2EF9-4CDA-A9EF-C357C93AA424

P2860

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

http://www.wikidata.org/entity/Q36088957

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@ast

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@en

type

label

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@ast

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@en

prefLabel

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@ast

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@en

P1433

Q36088957-B73BD0C9-6F15-4263-A0FC-952D5E9BA54E

P1476

Q36088957-A6BE8067-A98D-49FB-AD9E-19893CF9C47F

P2093

Q36088957-B7508291-AE94-4CC5-9906-242160E4D393

P2860

Q36088957-01A0B2EB-B4F2-4A3B-B697-E7D512A3EE95

Q36088957-05E2ABB2-E1F0-4CE5-985D-B8BB0D38162B

Q36088957-06FC4533-6B72-4DA9-9899-EE85283F401C

Q36088957-0EC9886B-C9EB-4F3C-85A2-1C2B7AA10CB1

Q36088957-191AD67B-D1F4-477F-AEA6-EDEC169BE985

Q36088957-1ECACE35-A6B8-4E7F-A169-F11C82A4A37B

Q36088957-201657FA-0FAF-4051-8B3F-0D41B3030C6B

Q36088957-2ABADF7D-C964-4526-8749-D2267DDFB011

Q36088957-2C25D8B2-5300-4FA1-A21F-12BCB5548037

Q36088957-335464CB-D76B-492A-8632-AA91C6F9E144

P304

Q36088957-F017CCA4-F217-4DBE-B4AE-E24BB5854A59

P31

Q36088957-ECA731E4-EC93-46E0-B24F-0F9FFF76C250

P356

Q36088957-33C29ECF-A6D5-42AF-906F-929A688CD490

P478

Q36088957-E6FC5491-0F0F-42D5-8044-124D39B6347E

P577

Q36088957-21442718-0C44-4B85-A283-EAD7774C9748

P698

Q36088957-11FDDF08-6214-4466-A3BE-85DA6EC24D01

P356

P1433

Human Molecular Genetics

P1476

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes.

@en

P2093

Richard J Gibbons

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation

Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily

The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein

Regulation of p53 activity through lysine methylation

Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome)

A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells.

Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG

Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

P304

R85-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDI106

http://www.w3.org/2001/XMLSchema#string

P478

14 Spec No 1

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15809277

http://www.w3.org/2001/XMLSchema#string